- Home
- CLDI vs MDRR Comparison
CLDI vs MDRR Comparison
Compare CLDI & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- MDRR
- Stock Information
- Founded
- CLDI 2014
- MDRR 2015
- Country
- CLDI United States
- MDRR United States
- Employees
- CLDI N/A
- MDRR N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- MDRR Real Estate Investment Trusts
- Sector
- CLDI Health Care
- MDRR Real Estate
- Exchange
- CLDI Nasdaq
- MDRR Nasdaq
- Market Cap
- CLDI 20.2M
- MDRR 17.1M
- IPO Year
- CLDI N/A
- MDRR 2018
- Fundamental
- Price
- CLDI $1.60
- MDRR $13.44
- Analyst Decision
- CLDI
- MDRR
- Analyst Count
- CLDI 0
- MDRR 0
- Target Price
- CLDI N/A
- MDRR N/A
- AVG Volume (30 Days)
- CLDI 484.3K
- MDRR 6.5K
- Earning Date
- CLDI 11-11-2025
- MDRR 11-11-2025
- Dividend Yield
- CLDI N/A
- MDRR 1.95%
- EPS Growth
- CLDI N/A
- MDRR N/A
- EPS
- CLDI N/A
- MDRR N/A
- Revenue
- CLDI N/A
- MDRR $9,649,145.00
- Revenue This Year
- CLDI N/A
- MDRR N/A
- Revenue Next Year
- CLDI N/A
- MDRR N/A
- P/E Ratio
- CLDI N/A
- MDRR N/A
- Revenue Growth
- CLDI N/A
- MDRR N/A
- 52 Week Low
- CLDI $1.51
- MDRR $9.55
- 52 Week High
- CLDI $46.68
- MDRR $15.00
- Technical
- Relative Strength Index (RSI)
- CLDI 30.60
- MDRR 59.06
- Support Level
- CLDI $1.51
- MDRR $13.05
- Resistance Level
- CLDI $1.68
- MDRR $13.87
- Average True Range (ATR)
- CLDI 0.10
- MDRR 0.32
- MACD
- CLDI 0.14
- MDRR 0.04
- Stochastic Oscillator
- CLDI 22.97
- MDRR 61.83
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.